4-[[4-[[4-Carbamoyl-2-(naphthalen-2-ylamino)-1,3-thiazol-5-yl]carbamoyl]phenyl]methyl]piperazine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-[[4-[[4-Carbamoyl-2-(naphthalen-2-ylamino)-1,3-thiazol-5-yl]carbamoyl]phenyl]methyl]piperazine-1-carboxylic acid
• 英文别名: 4-[[4-[[4-carbamoyl-2-(naphthalen-2-ylamino)-1,3-thiazol-5-yl]carbamoyl]phenyl]methyl]piperazine-1-carboxylic acid
• 化学式: C₂₇H₂₆N₆O₄S
• 分子量: 530.6
• InChiKey: DBPBLBNYALMLGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  169
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• NOVEL BICYCLIC THIAZOLE COMPOUNDS
  申请人：Carna Biosciences, Inc.

  公开号：EP2855470A1

  公开（公告）日：2015-04-08
• [EN] NOVEL BICYCLIC THIAZOLE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THIAZOLES BICYCLIQUES
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2013176293A1

  公开（公告）日：2013-11-28

  The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.